What Happened

uniQure released initial six-month data from its Phase I/IIa trial of AMT-260, showing three of six refractory MTLE patients achieved 79%-100% seizure reduction at low dose (1x10^12 gc/mL). No serious adverse events were reported, with headaches being the most common side effect.

Who Is Affected

This impacts approximately 300,000 refractory MTLE patients in the U.S. who don't respond to anti-seizure medications. Neurologists and epilepsy treatment centers serving this population will be evaluating AMT-260's potential as enrollment continues in higher-dose cohorts.

Market Impact

• Validates gene therapy approach for refractory epilepsy
• Creates potential disruption for anti-seizure medication market
• Positions uniQure as leader in neurology gene therapy

What to Watch

Second cohort (3x10^12 gc/mL) enrollment completes mid-2026, with updated trial results expected H1 2027. Monitor for partnerships with epilepsy treatment networks as uniQure advances this program.